Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

This study tests a new biologic drug called FB704A in adults with severe asthma that is not well-controlled. The drug targets neutrophils — a type of immune cell involved in certain types of difficult-to-treat asthma. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with severe asthma (according to international guidelines) - Your asthma symptoms are poorly controlled (ACT score below 20) - A high proportion of your sputum cells are neutrophils (50% or more) - Your asthma diagnosis is documented from within the past 5 years - You show evidence of airway reversibility or airway hyperresponsiveness on breathing tests **You may NOT be eligible if...** - You have mild or moderate (not severe) asthma - Your asthma does not involve neutrophil-dominated inflammation - You are pregnant or breastfeeding - You have other serious lung diseases, active infections, or autoimmune conditions - You are already taking certain biologic asthma treatments Talk to your doctor to see if this trial is right for you.